Join
Live feed
·
PRReleasevia Quantisnow
CERo Therapeutics Holdings Inc. logo

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

ByQuantisnow·Wall Street's wire, on your screen.
CERO· CERo Therapeutics Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CERO (CERo Therapeutics Holdings Inc.) and more on Quantisnow.